Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients.

Literature DB >> 18832886

Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients.

Cathia Soulié¹, Isabelle Malet, Sidonie Lambert-Niclot, Roland Tubiana, Monique Thévenin, Anne Simon, Robert Murphy, Christine Katlama, Vincent Calvez, Anne-Geneviève Marcelin.

Abstract

Resistance to CCR5 antagonists can be driven by mutations in gp120. Sequences from 323 anti-CCR5 naive patients were analyzed for the presence of previously described in-vivo or in-vitro resistance mutations to CCR5 antagonists located in the V3 loop of gp120. The V3 loop region was rather polymorphic, and 7.3% of patients showed viruses with combinations of mutations in V3 loop previously described to be involved in maraviroc resistance, a licensed CCR5 antagonist.

Entities: Gene Species

Mesh：

Substances：

Year: 2008 PMID： 18832886 DOI： 10.1097/QAD.0b013e328313bf9c

Source DB: PubMed Journal: AIDS ISSN： 0269-9370 Impact factor: 4.177

Keyword Cloud
Cited

9 in total

1. Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study.

Authors: Patricia Recordon-Pinson; Cathia Soulié; Philippe Flandre; Diane Descamps; Mouna Lazrek; Charlotte Charpentier; Brigitte Montes; Mary-Anne Trabaud; Jacqueline Cottalorda; Véronique Schneider; Laurence Morand-Joubert; Catherine Tamalet; Delphine Desbois; Muriel Macé; Virginie Ferré; Astrid Vabret; Annick Ruffault; Coralie Pallier; Stéphanie Raymond; Jacques Izopet; Jacques Reynes; Anne-Geneviève Marcelin; Bernard Masquelier
Journal: Antimicrob Agents Chemother Date: 2010-06-07 Impact factor: 5.191

9. V3-Loop genotypes do not predict maraviroc susceptibility of CCR5-tropic virus or clinical response through week 48 in HIV-1-infected, treatment-experienced persons receiving optimized background regimens.

Authors: M E Lewis; P Simpson; J Mori; B Jubb; J Sullivan; L McFadyen; E van der Ryst; C Craig; D L Robertson; M Westby
Journal: Antivir Chem Chemother Date: 2021 Jan-Dec

9 in total

Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients.

1. Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study.

Review 2. Novel targets for antiretroviral therapy: clinical progress to date.

Review 3. Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection.

Review 4. Next-generation oral preexposure prophylaxis: beyond tenofovir.

5. Template-constrained cyclic sulfopeptide HIV-1 entry inhibitors.

6. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo.

Review 7. Clinical use of CCR5 inhibitors in HIV and beyond.

8. Genetic characteristics, coreceptor usage potential and evolution of Nigerian HIV-1 subtype G and CRF02_AG isolates.

9. V3-Loop genotypes do not predict maraviroc susceptibility of CCR5-tropic virus or clinical response through week 48 in HIV-1-infected, treatment-experienced persons receiving optimized background regimens.